Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis

Internal Medicine

Volumn 49, Issue 15, 2010, Pages 1587-1591

  Asamiya, Yukari ^a   Moriyama, Takahito ^a   Takano, Mari ^a   Iwasaki, Chihiro ^a   Kimura, Kazuo ^a   Ando, Yukako ^a   Aoki, Akiko ^a   Kikuchi, Kan ^b   Takei, Takashi ^a   Uchida, Keiko ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Shimo Ochiai Clinic   (Japan)

Author keywords

ANCA associated vasculitis; Hemodialysis; Intrapulmonary hemorrhage; Renal failure; Rituximab; TTP

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; FRESH FROZEN PLASMA; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABSENCE OF SIDE EFFECTS; ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; EMOTIONAL DISORDER; FEMALE; HEADACHE; HEMATURIA; HEMODIALYSIS; HUMAN; HYDRONEPHROSIS; INTENSIVE CARE; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LUNG HEMORRHAGE; PERSONALITY DISORDER; PLASMAPHERESIS; PROTEINURIA; REMISSION; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UROLITHIASIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77956223125     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3135     Document Type: Article

References (24)

1. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60: 2156-2168, 2009.
2. Oh JS, Lee CK, Kim YG, et al. Clinical features and outcomes of microscopic polyangiitis in Korea. J Korean Med Sci 24: 269-274, 2009.
3. Nagai K, Kotani T, Takeuchi T, et al. Successful treatment of thrombotic thrombocytopenic purpura with repeated plasma exchange in a patient with microscopic polyangiitis. Mod Rheumatol 18: 643-646, 2008.
4. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 84: 418-421, 2009.
5. Scaramucci L, Niscola P, Palumbo R, et al. Rapid response and sustained remission by rituximab in four cases of plasmaexchange- failed acute thrombotic thrombocytopenic purpura. Int J Hematol 89: 389-399, 2009.
6. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 101: 233-238, 2009.
7. Sakai H, Kurokawa K, Koyama A, et al; Committee for the Guidelines on Diagnosis and Therapy of Rapidly Progressive Glomerulonephritis. The guidelines for the management of rapidly progressive glomerulonephritis. Jpn J Nephrol 44: 55-82, 2002 (in Japanese).
8. Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 74: 17-22, 2003.
9. Yumura W, Ito C. Activity of ANCA related vasculitis and the value of organ-injury. J Jpn Coll Angiol 49: 63-73, 2009.
10. Fujimura Y, Matsumoto M, Yagi H, et al. Von Willebrand factorcleaving protease and Upshaw-Schulman syndrome. Int J Hematol 75: 25-34, 2002.
11. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339: 1585-1594, 1998.
12. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89: 3097-3103, 1997.
13. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120: 556-573, 2003.
14. Sarode R, Gottschall JL, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 54: 102-107, 1997.
15. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325: 393-397, 1991.
16. Fujimura Y. Progress on TTP/HUS diagnosis with analysis of VWF-cleaving protease activation. Nippon Naika Gakkai Zasshi 93: 451-459, 2004 (in Japanese).
17. Kameda T, Dobashi H, Kittaka K, et al. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol 26: 2159-2162, 2007.
18. Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 41: 4-14, 2004.
19. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60: 2156-2168, 2009.
20. Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45: 1432-1436, 2006.
21. Hasegawa M, Hasegawa M. B lymphocyte. Nihon Rinsho Meneki Gakkai Kaishi 28: 300-308, 2005 (in Japanese).
22. Willis MS, Bandarenko N. Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Semin Thromb Hemost 31: 700-708, 2005.
23. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 93: 930-933, 2008.
24. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after therapy with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94: 2217-2224, 1999.